Biosimilar Insulin Aspart Demonstrates Equivalent Glycemic Control to Originator in Type 1 Diabetes
A multicenter retrospective cohort study across 34 Chinese hospitals found that biosimilar insulin aspart provided glycemic control and safety comparable ...










